Company intelligence / Profile preview

Aerocrine

Ownership: Private
Development stage: Other

Overview

Aerocrine pioneered the measurement of fractional exhaled nitric oxide (FeNO) as a non-invasive biomarker for airway inflammation. Its devices—NIOX MINO®, NIOX VERO®, and earlier models—are used globally to aid in asthma diagnosis and management. The company’s products have been recommended by NICE in the UK and are widely adopted in clinical practice[1][2][3]. Clinical results show that FeNO testing improves asthma diagnosis accuracy and helps guide anti-inflammatory therapy. Over 50 million FeNO tests have been performed with this technology[4].

Therapeutic areas: Pulmonology
Modalities: DeviceDiagnostic device (FeNO testing)
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on Aerocrine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aerocrine.

Explore the full profile